Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.57 |
| ▸ | TYMP | P19971 | 1/20 | 0.51 |
| ▸ | NT5E | P21589 | 2/20 | 0.49 |
| ▸ | HINT1 | P49773 | 1/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.48 |
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9753476 | 0.92 | POLB (0.68) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL1401380 | 0.90 | POLB (0.56) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL8490891 | 0.89 | POLB (0.71) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL442294 | 0.89 | POLB (0.71) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL338650 | 0.88 | POLB (0.70) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL16359949 | 0.88 | POLB (0.70) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL15798769 | 0.88 | POLB (0.70) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL15012843 | 0.88 | POLB (0.70) | POLBP2RY2P2RY4P2RY6TYMP | |
| Deoxyguanosine SCHEMBL3360864 | 0.88 | POLB (0.63) | POLBP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL11421357 | 0.88 | POLB (0.67) | POLBP2RY2P2RY4P2RY6TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828218-B1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2014-04-30 | — | — | EP | claimed |
| US-20130281682-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2013-10-24 | — | — | US | claimed |
| US-20120316328-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2012-12-13 | — | — | US | claimed |
| US-20100081802-A1 | Synthesis of Phosphitylated Compounds Using a Quaternary Heterocyclic Activator | GIRINDUS AG (DE) | 2010-04-01 | — | — | US | claimed |
| EP-1828218-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | Girindus AG (DE) | 2007-09-05 | — | — | EP | claimed |
| WO-2006064039-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2006-06-22 | — | — | WO | claimed |
| US-12406750-B2 | Encoding digital data using oligonucleotides | LENOVO (SINGAPORE) PTE. LTD. (SG) | 2025-09-02 | — | — | US | disclosed |
| US-20250078958-A1 | ENCODING DIGITAL DATA USING OLIGONUCLEOTIDES | LENOVO (SINGAPORE) PTE. LTD. (SG) | 2025-03-06 | — | — | US | disclosed |
| US-20240286104-A1 | POLYANILINE COATED ELECTRODES FOR POLYMER SYNTHESIS | LENOVO (SINGAPORE) PTE. LTD. (SG) | 2024-08-29 | — | — | US | disclosed |
| EP-1828218-B1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2014-04-30 | — | — | EP | disclosed |
| US-20130281682-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20120316328-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | GIRINDUS AG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-8247540-B2 | Caged nucleotides and oligonucleotides and their application | DEITERS ALEXANDER (US) | 2012-08-21 | — | — | US | disclosed |
| US-20010029296-A1 | Minimization of blooming in high-density arrays by using reactive wash reagents | PERBOST MICHEL G M (US) | 2001-10-11 | — | — | US | disclosed |
| US-6300137-B1 | APPLYING CAPPING AGENT TO THE SUBSTRATE TO DEACTIVATE ANY UNREACTED DEPROTECTED BOUND OLIGONUCLEOTIDE, 5'-PROTECTED NUCLEOSIDE PHOSPHORAMIDITES ARE APPLIED IN DROPLETS HAVING COVERING VOLUMES TO FULLY COVER THE FIRST DROPLET; ACCURACY | AGILENT TECHNOLOGIES INC. | 2001-10-09 | — | — | US | disclosed |
| US-6184347-B1 | Minimization of blooming in high-density arrays by using reactive wash reagents | AGILENT TECHNOLOGIES INC. | 2001-02-06 | — | — | US | disclosed |
| EP-0691981-A1 | TUMOR TARGETING WITH L-ENANTIOMERIC OLIGONUCLEOTIDE CONJUGATES OF IMMUNOREAGENTS AND OF CHELATED RADIONUCLIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994020523-A1 | TUMOR TARGETING WITH L-ENANTIOMERIC OLIGONUCLEOTIDE CONJUGATES OF IMMUNOREAGENTS AND OF CHELATED RADIONUCLIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
| WO-1989009780-A1 | SITE-SPECIFIC TRITIUM-LABELED OLIGODEOXYNUCLEOTIDES | CHEMICAL INDUSTRY INSTITUTE OF TOXICOLOGY (US) | 1989-10-19 | — | — | WO | disclosed |
| WO-1989009778-A1 | OLIGONUCLEOTIDE CONTAINING 6-THIOGUANINE AT A PREDETERMINED SITE | CHEMICAL INDUSTRY INSTITUTE OF TOXICOLOGY (US) | 1989-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240286104-A1 | POLYANILINE COATED ELECTRODES FOR POLYMER SYNTHESIS | POLRMT, NSUN2, POLI | POLB 30/4885P2RY2 4604/4885P2RY4 4071/4885 |
| US-20100081802-A1 | Synthesis of Phosphitylated Compounds Using a Quaternary Heterocyclic Activator | ARAF, ATIC, PFKFB3 | POLB 2894/4885P2RY2 33/4885P2RY4 48/4885 |
| US-20120316328-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | ARAF, ATIC, PFKFB3 | POLB 3100/4885P2RY2 27/4885P2RY4 41/4885 |
| US-20130281682-A1 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR | ARAF, ATIC, HK2 | POLB 3155/4885P2RY2 37/4885P2RY4 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.